Development History and Feasibility Analysis of Mesenchymal Stem Cell Therapy for Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) has become a major global public health burden, and existing drugs cannot reverse the progressive failure of pancreatic β-cell function. Mesenchymal stem cells (MSCs), by virtue of their immunomodulatory, anti-inflammatory, and tissue-repair properties, offer a new strategy for the causal treatment of T2DM. This article reviews the development history and mechanisms of action of MSC therapy for T2DM, including restoration of insulin-resistance signaling pathways, reversal of β-cell dedifferentiation, suppression of chronic low-grade inflammation, and exosome-mediated paracrine effects; summarizes evidence from preclinical animal studies and recent representative clinical studies, analyzing safety and efficacy; and discusses translational bottlenecks such as cellular heterogeneity, low homing efficiency, and the lack of standardization, together with countermeasures including genetic modification, patient stratification, and exosome engineering. Current evidence indicates that MSC therapy for T2DM is safe and feasible, with glucose-lowering and organ-protective potential; however, complete remission rates are low and therapeutic responses are highly heterogeneous, and routine clinical application still requires high-quality evidence-based support and standardized systems.

Authors

Institutions

Publication Details

Journal
Theoretical and Natural Science
Published
2026-11-17
DOI
https://doi.org/10.54254/2753-8818/2027.kl39007
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development History and Feasibility Analysis of Mesenchymal Stem Cell Therapy for Type 2 Diabetes Mellitus

Haotian Yang
Theoretical and Natural Science
Mesenchymal stem cell research
article

Development History and Feasibility Analysis of Mesenchymal Stem Cell Therapy for Type 2 Diabetes Mellitus

Haotian Yang
article en

Abstract

Type 2 diabetes mellitus (T2DM) has become a major global public health burden, and existing drugs cannot reverse the progressive failure of pancreatic β-cell function. Mesenchymal stem cells (MSCs), by virtue of their immunomodulatory, anti-inflammatory, and tissue-repair properties, offer a new strategy for the causal treatment of T2DM. This article reviews the development history and mechanisms of action of MSC therapy for T2DM, including restoration of insulin-resistance signaling pathways, reversal of β-cell dedifferentiation, suppression of chronic low-grade inflammation, and exosome-mediated paracrine effects; summarizes evidence from preclinical animal studies and recent representative clinical studies, analyzing safety and efficacy; and discusses translational bottlenecks such as cellular heterogeneity, low homing efficiency, and the lack of standardization, together with countermeasures including genetic modification, patient stratification, and exosome engineering. Current evidence indicates that MSC therapy for T2DM is safe and feasible, with glucose-lowering and organ-protective potential; however, complete remission rates are low and therapeutic responses are highly heterogeneous, and routine clinical application still requires high-quality evidence-based support and standardized systems.

Theoretical and Natural ScienceVol. 195(1)
Southwest Jiaotong University (CN)
Good health and well-being
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon